Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2025-08-25 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
赛伦生物：2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2025 Half-Year Report Summary' (半年度报告摘要) for Shanghai Serum Biotech Co., Ltd. It contains financial data for the half-year period, including total assets, net profit, revenue, and other key financial metrics. It also includes shareholder information and dividend distribution plans for the half-year period. The document explicitly states it is a half-year report summary and references the full half-year report for detailed information. The length is 3530 characters, which is relatively short but contains substantive financial data and analysis for a period shorter than a full fiscal year. It is not merely an announcement or a certification but contains actual financial figures and management discussion. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-25 Chinese
赛伦生物：2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "上海赛伦生物技术股份有限公司2025 年半年度报告" which translates to "Shanghai Serum Bio-Technology Co., Ltd. 2025 Semi-Annual Report." It covers the period from January 1, 2025 to June 30, 2025, indicating it is a report for a period shorter than a full fiscal year. The content includes detailed financial data such as revenue, net profit, cash flow, and financial indicators, as well as management discussion and analysis, business overview, product descriptions, and R&D updates. The document is comprehensive and contains actual financial statements and substantive financial analysis. It is explicitly stated as a "半年度报告" (half-year report), which corresponds to an Interim / Quarterly Report. The document is not a brief announcement or a certification letter, so it is not Regulatory Filings or Report Publication Announcement. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2025
2025-08-25 Chinese
赛伦生物：关于2025年半年度利润分配方案的公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement from Shanghai SAILUN Biotechnology Co., Ltd. regarding the 2025 semi-annual profit distribution plan. It details the dividend per share, total dividend amount, and the basis for distribution. It also mentions the authorization from the 2024 annual general meeting and the board meeting approval. The document is short (1491 characters) and focuses on the dividend distribution plan rather than providing full financial statements or comprehensive financial analysis. It does not contain detailed financial results or management discussion but is specifically about the dividend amount and payment details. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2025-08-25 Chinese
方正证券承销保荐有限责任公司关于上海赛伦生物技术股份有限公司使用自有资金支付募投项目人员费用并以募集资金等额置换的核查意见
Regulatory Filings Classification · 65% confidence The document is a verification opinion (“核查意见”) issued by the sponsoring underwriter (方正证券承销保荐有限责任公司) regarding the company's use of self-funds and subsequent replenishment with IPO proceeds. It is not a financial report (10-K, IR, ER), not an AGM or proxy material, and not an audit report by an accounting firm. Rather, it is a compliance filing required by listing rules. It therefore falls under the general regulatory announcements and compliance documents category, RNS.
2025-08-25 Chinese
赛伦生物：2025年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2025 Half-Year Special Report on the Deposit and Actual Use of Raised Funds" by Shanghai SAILUN Biotechnology Co., Ltd. It details the management, usage, and balance of funds raised through a public stock issuance, including specific project expenditures, cash management, and regulatory compliance. The document references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange, and it provides detailed financial figures related to fundraising and usage for the half-year period ending June 30, 2025. The content focuses on the use and management of raised capital rather than presenting comprehensive financial statements or overall company performance. This aligns with the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length (7464 characters) and detailed financial data support this classification rather than a simple announcement or a full annual/interim report.
2025-08-25 Chinese
赛伦生物：关于自愿披露抗狂犬病血清挂网销售的公告
Capital/Financing Update Classification · 90% confidence The document is a voluntary disclosure announcement by Shanghai Sairen Biotechnology Co., Ltd. regarding the listing and sales of their anti-rabies serum product on provincial drug procurement platforms. It provides product details, market context, and risk warnings but does not contain financial statements, earnings data, or regulatory certifications. The document is relatively short (1387 characters) and serves as an operational update about product commercialization and its potential impact on company performance. It is not an earnings release, annual or interim report, nor a regulatory filing or certification. It is an announcement about a product sales update, which fits best under Capital/Financing Update (CAP) as it relates to business development and potential revenue growth from a new product sales channel.
2025-08-25 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.